GlobeNewswire·Nov 9, 2026, 4:05 PM ET

OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion

OraSure Technologies reported 14% year-over-year revenue growth for the quarter ended September 30, 2026, totaling $30.9 million.
GAAP gross margin improved by over 170 basis points to 45.2% compared to the prior year quarter.
The company received initial orders for the Colli-Pee®•Dx Urine Collection Kit & OraQuick® Ebola 2.0 Rapid Antigen Test.
Core business revenues grew 14% year-over-year, driven by 16% growth in Diagnostics & 21% growth in Sample Management Solutions.
GAAP net loss for the quarter was $13.1 million, while non-GAAP net loss was $10.1 million.
Cash & cash equivalents stood at $148.2 million as of September 30, 2026.
The company guides Q4 2026 total revenues between $30.0 million & $32.0 million.
OraSure expects an acceleration of full-year revenue growth in 2027 compared to 2026.
Full-year 2026 revenue is projected to grow 4.7% year-over-year at the midpoint of the guidance range.
Diagnostics revenue reached $16.8 million, attributed to higher HIV & HCV revenues & sales from BioMedomics' Sickle SCAN®.
Sample Management Solutions revenue reached $12.5 million, driven by key commercial customer growth & order timing.
Operating expenses decreased due to operational efficiency initiatives reducing the cost base.
The company advanced early development of HPV testing as a potential future application for the Colli-Pee®•Dx platform.